Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

NCT05536128 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: Olaparib
DRUG: Fulvestrant

Sponsor

Seoul National University Hospital